Published • loading... • Updated
Magnite (NASDAQ:MGNI) Shares Gap Up - Here's What Happened
The 12-patient study showed a 61% slowing at three years, but analysts said updated control data may understate AMT-130's effect.
- On Tuesday, UniQure reported its gene therapy AMT-130 slowed Huntington's disease progression by 44% at four years, though shares plummeted 40% to trade just below $24 following the disclosure.
- While the therapy showed a 44% slowdown, the result lacked statistical significance; UniQure noted that 53% of 48-month reference data was missing, likely understating the treatment effect.
- Analysts at Stifel and Leerink Partners noted three-year data from 15 high-dose patients appeared robust, showing 80% and 67% slowing of disease progression compared to external controls.
- The Food and Drug Administration is reviewing UniQure's marketing application for AMT-130, with a verdict expected in about eight months as the company reported a $135 million net loss this year.
- Despite mixed results, the Netherlands-based company maintains AMT-130 demonstrates a "meaningful" effect on Huntington's disease, noting rare disease communities often accept greater risks for potential treatment options.
Insights by Ground AI
14 Articles
14 Articles
uniQure Stock Crashed on Its Huntington's Data. Wall Street's Price Target Says the Selloff Went Too Far
uniQure lost more than a third of its value in a single session after Huntington's data spooked investors, but Wall Street's price target still points to triple-digit upside. Whether that gap represents opportunity or denial depends on one number that cuts both ways.
·Lakewood, United States
Read Full Article
UniQure’s Huntington’s therapy fails to significantly slow disease progression, shares plunge
Sept 29 (Reuters) - UniQure said its gene therapy for Huntington's disease fell short of statistical significance on the main goal of slowing disease progression in a four-year analysis, sending its U.S.-listed shares plummeting 55% in premarket ...
Coverage Details
Total News Sources14
Leaning Left1Leaning Right1Center7Last UpdatedBias Distribution78% Center
Bias Distribution
- 78% of the sources are Center
78% Center
11%
C 78%
11%
Factuality
To view factuality data please Upgrade to Premium
